Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 3Unknown 2Terminated 2Completed 2Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Prostatic Neoplasms 7Neoplasm Metastasis 2Triple Negative Breast Neoplasms 1Salivary Gland Neoplasms 1Paget Disease, Extramammary 1Non-Muscle Invasive Bladder Urothelial Carcinoma 1Non-Muscle Invasive Bladder Neoplasms 1Carcinoma, Renal Cell 1Bulbo-Spinal Atrophy, X-Linked 1Breast Neoplasms 1

Interventions

Fulvestrant 58Trastuzumab 49Capecitabine 48Letrozole 45pembrolizumab 41Carboplatin 41Paclitaxel 39Cyclophosphamide 38ribociclib 37pertuzumab 36abemaciclib 36Blood Specimen Collection 31Specimen Handling 28trastuzumab deruxtecan 27Docetaxel 27Surveys and Questionnaires 26Anastrozole 25exemestane 24Tamoxifen 24palbociclib 21130-nm albumin-bound paclitaxel 21Magnetic Resonance Spectroscopy 20Biopsy 19sacituzumab govitecan 18eribulin 18Radiotherapy 18Gemcitabine 18olaparib 17Injections 17Epirubicin 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Breast Neoplasms × bicalutamide × Clear all
NCT05095207 2026-04-13

Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

Icahn School of Medicine at Mount Sinai

Phase 1/2 Recruiting
42 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡